総資産利益率 (ROA)
2005年以降
計算
Eli Lilly & Co.、 ROA、長期トレンド計算
| ROA | = | 100 | × | 当期純利益(損失)1 | ÷ | 総資産1 | |
|---|---|---|---|---|---|---|---|
| 2023/12/31 | 8.19% | = | 100 | × | 5,240,400) | ÷ | 64,006,300) |
| 2022/12/31 | 12.62% | = | 100 | × | 6,244,800) | ÷ | 49,489,800) |
| 2021/12/31 | 11.44% | = | 100 | × | 5,581,700) | ÷ | 48,806,000) |
| 2020/12/31 | 13.28% | = | 100 | × | 6,193,700) | ÷ | 46,633,100) |
| 2019/12/31 | 21.17% | = | 100 | × | 8,318,400) | ÷ | 39,286,100) |
| 2018/12/31 | 7.36% | = | 100 | × | 3,232,000) | ÷ | 43,908,400) |
| 2017/12/31 | -0.45% | = | 100 | × | (204,100) | ÷ | 44,981,000) |
| 2016/12/31 | 7.05% | = | 100 | × | 2,737,600) | ÷ | 38,805,900) |
| 2015/12/31 | 6.77% | = | 100 | × | 2,408,400) | ÷ | 35,568,900) |
| 2014/12/31 | 6.43% | = | 100 | × | 2,390,500) | ÷ | 37,178,200) |
| 2013/12/31 | 13.29% | = | 100 | × | 4,684,800) | ÷ | 35,248,700) |
| 2012/12/31 | 11.89% | = | 100 | × | 4,088,600) | ÷ | 34,398,900) |
| 2011/12/31 | 12.92% | = | 100 | × | 4,347,700) | ÷ | 33,659,800) |
| 2010/12/31 | 16.35% | = | 100 | × | 5,069,500) | ÷ | 31,001,400) |
| 2009/12/31 | 15.76% | = | 100 | × | 4,328,800) | ÷ | 27,460,900) |
| 2008/12/31 | -7.09% | = | 100 | × | (2,071,900) | ÷ | 29,212,600) |
| 2007/12/31 | 11.02% | = | 100 | × | 2,953,000) | ÷ | 26,787,800) |
| 2006/12/31 | 12.13% | = | 100 | × | 2,662,700) | ÷ | 21,955,400) |
| 2005/12/31 | 8.05% | = | 100 | × | 1,979,600) | ÷ | 24,580,800) |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
1 千米ドル
競合他社との比較
Eli Lilly & Co.、 ROA、長期トレンド、競合他社との比較
| Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023/12/31 | 8.19% | 3.61% | 6.91% | 8.43% | 5.64% | 9.12% | 20.98% | 0.34% | -25.58% | 0.94% | 11.95% | 6.07% |
| 2022/12/31 | 12.62% | 8.53% | 10.06% | 6.53% | 8.55% | 7.27% | 9.57% | 13.30% | 32.34% | 15.91% | 14.85% | 7.15% |
| 2021/12/31 | 11.44% | 7.88% | 9.63% | 6.40% | 7.73% | 9.16% | 11.47% | 12.35% | 49.46% | 12.11% | 31.75% | 8.12% |
| 2020/12/31 | 13.28% | 3.07% | 11.54% | -7.61% | 4.79% | 0.18% | 8.41% | 7.72% | -10.18% | 6.23% | 20.47% | 9.23% |
| 2019/12/31 | 21.17% | 8.84% | 13.13% | 2.65% | 4.85% | 8.74% | 9.59% | 11.66% | -32.34% | 9.72% | 14.29% | 6.33% |
| 2018/12/31 | 7.36% | 9.58% | 12.64% | 14.06% | 5.54% | 8.57% | 10.00% | 7.53% | -19.61% | 7.00% | 20.83% | 5.22% |
| 2017/12/31 | -0.45% | 7.50% | 2.48% | 3.00% | 5.34% | 6.58% | 0.83% | 2.72% | — | 12.40% | 13.67% | 3.93% |
| 2016/12/31 | 7.05% | 9.01% | 9.95% | 13.22% | 5.64% | 23.70% | 11.71% | 4.11% | — | 4.20% | 12.84% | 4.40% |
| 2015/12/31 | 6.77% | 9.70% | 9.69% | 4.93% | 6.96% | 34.93% | 11.55% | 4.36% | — | 4.16% | 11.34% | 4.83% |
| 2014/12/31 | 6.43% | 6.44% | 7.47% | 5.94% | 7.02% | 34.91% | 12.45% | 12.12% | — | 5.40% | 8.99% | 4.42% |
| 2013/12/31 | 13.29% | 14.14% | 7.68% | 6.64% | 7.77% | 13.67% | 10.42% | 4.17% | — | 12.78% | 14.38% | 4.00% |
| 2012/12/31 | 11.89% | 19.53% | 8.00% | 5.46% | 7.26% | 12.20% | 8.94% | 5.81% | — | 7.84% | 36.06% | 4.29% |
| 2011/12/31 | 12.92% | — | 7.54% | 11.25% | 7.25% | 16.20% | 8.51% | 5.97% | — | 5.32% | -16.75% | 4.96% |
| 2010/12/31 | 16.35% | — | 10.64% | 9.98% | 8.07% | 25.03% | 12.96% | 0.81% | — | 4.23% | -9.59% | 4.85% |
| 2009/12/31 | 15.76% | — | 11.62% | 34.22% | 5.88% | 27.18% | 12.95% | 11.51% | — | 4.05% | -9.15% | 3.93% |
| 2008/12/31 | -7.09% | — | 11.51% | 17.76% | 7.53% | 28.65% | 15.25% | 16.54% | — | 7.29% | -12.34% | 4.71% |
| 2007/12/31 | 11.02% | — | 9.14% | 8.27% | 7.84% | 27.68% | 13.06% | 6.77% | — | 7.07% | -11.28% | 3.59% |
| 2006/12/31 | 12.13% | — | 8.73% | 6.20% | 8.72% | -29.12% | 15.67% | 9.95% | — | 16.84% | -17.49% | 0.79% |
| 2005/12/31 | 8.05% | — | 12.54% | 10.66% | 9.80% | 21.62% | 17.94% | 10.33% | — | 6.88% | -22.54% | 5.25% |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
Eli Lilly & Co.、 ROA、長期トレンド、産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
| Eli Lilly & Co. | 製薬、バイオテクノロジー、ライフサイエンス | |
|---|---|---|
| 2023/12/31 | 8.19% | 6.57% |
| 2022/12/31 | 12.62% | 11.04% |
| 2021/12/31 | 11.44% | 11.19% |
| 2020/12/31 | 13.28% | 5.14% |
| 2019/12/31 | 21.17% | 8.90% |
| 2018/12/31 | 7.36% | 8.71% |
| 2017/12/31 | -0.45% | 5.27% |
| 2016/12/31 | 7.05% | 8.66% |
| 2015/12/31 | 6.77% | 9.03% |
| 2014/12/31 | 6.43% | 9.59% |
| 2013/12/31 | 13.29% | 9.55% |
| 2012/12/31 | 11.89% | 8.35% |
| 2011/12/31 | 12.92% | 7.32% |
| 2010/12/31 | 16.35% | 7.23% |
| 2009/12/31 | 15.76% | 10.17% |
| 2008/12/31 | -7.09% | 10.52% |
| 2007/12/31 | 11.02% | 8.98% |
| 2006/12/31 | 12.13% | 12.00% |
| 2005/12/31 | 8.05% | 10.50% |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
業界との比較: 医療
Eli Lilly & Co.、 ROA、長期トレンド、業界との比較: 医療
| Eli Lilly & Co. | 医療 | |
|---|---|---|
| 2023/12/31 | 8.19% | 6.08% |
| 2022/12/31 | 12.62% | 8.60% |
| 2021/12/31 | 11.44% | 8.69% |
| 2020/12/31 | 13.28% | 5.36% |
| 2019/12/31 | 21.17% | 7.15% |
| 2018/12/31 | 7.36% | 6.08% |
| 2017/12/31 | -0.45% | 5.31% |
| 2016/12/31 | 7.05% | 6.93% |
| 2015/12/31 | 6.77% | 7.37% |
| 2014/12/31 | 6.43% | 8.18% |
| 2013/12/31 | 13.29% | 8.29% |
| 2012/12/31 | 11.89% | 7.68% |
| 2011/12/31 | 12.92% | 7.00% |
| 2010/12/31 | 16.35% | 6.99% |
| 2009/12/31 | 15.76% | 9.19% |
| 2008/12/31 | -7.09% | 8.56% |
| 2007/12/31 | 11.02% | 8.18% |
| 2006/12/31 | 12.13% | 9.77% |
| 2005/12/31 | 8.05% | 9.09% |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).